They have come into the limelight after a large double-blinded study published in NEJM, showed an average 14.9% decrease in weight in obese patients given semaglutide on top of lifestyle modifications, compared to 2.4% in the control arm (see research summary at end)
Does combining GLP-1 agonists produce better results
Caviness Distinguished Professor of Medicine and Director of the UNC Diabetes Care Center
As a result of these unprecedented dynamics and high demand for semaglutide products, we believe it is our responsibility to continue to raise awareness, to reinforce responsible use of our medicines and, ultimately, to support patient safety and positive clinical outcomes. When health care providers prescribe medications for unapproved uses, its known as an off-label use. Some off-label uses of medication can have benefits for patients, but there are also potential risks
In clinical trials, GLP-1RAs were well tolerated and effective at helping people prevent weight regain, and may be a good option for long-term weight control and lowering patients chances of serious health problems
